Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonnet BioTherapeutics Holdings's quarterly market cap
increased
from Dec. 2024 (€132.31 Mil) to Mar. 2025 (€137.41 Mil) and
increased
from Mar. 2025 (€137.41 Mil) to Jun. 2025 (€146.65 Mil).
Sonnet BioTherapeutics Holdings's annual market cap
increased
from Sep. 2022 (€8.42 Mil) to Sep. 2023 (€9.64 Mil) and
increased
from Sep. 2023 (€9.64 Mil) to Sep. 2024 (€28.60 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sonnet BioTherapeutics Holdings's Enterprise Value for Today is €7.19 Mil.
Sonnet BioTherapeutics Holdings (STU:H3D) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sonnet BioTherapeutics Holdings Market Cap Related Terms
Sonnet BioTherapeutics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:H3D vs CING, BOLD, DARE: Market Cap Comparison
For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonnet BioTherapeutics Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Sonnet BioTherapeutics Holdings's Market Cap falls into.
Sonnet BioTherapeutics Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonnet BioTherapeutics Holdings (STU:H3D) has a Market Cap of €7.41 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' Market Cap too high?
Sonnet BioTherapeutics Holdings' current Market Cap is €7.41 Mil. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' Market Cap compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' Market Cap of €7.41 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 117.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.38, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sonnet BioTherapeutics Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 117.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonnet BioTherapeutics Holdings's current Market Cap is €7.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (STU:H3D) has a current Market Cap of €7.41 Mil. The current Market Cap is €7.41 Mil. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (STU:H3D), the current Market Cap is €7.41 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sonnet BioTherapeutics Holdings Business Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score
Get the complete analysis for STU:H3D
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:H3D has been successfully added to your 
